1311 LONG-TERM BIOCHEMICAL RECURRENCE IN 3625 PATIENTS FOLLOWING ROBOT-ASSISTED RADICAL PROSTATECTOMY

Abstract

You have accessJournal of UrologyProstate Cancer: Localized1 Apr 20111311 LONG-TERM BIOCHEMICAL RECURRENCE IN 3625 PATIENTS FOLLOWING ROBOT-ASSISTED RADICAL PROSTATECTOMY Craig Rogers, Mireya Diaz, Sameer Siddiqui, Jesse Sammon, Shyam Sukumar, and Mani Menon Craig RogersCraig Rogers Detroit, MI More articles by this author , Mireya DiazMireya Diaz Detroit, MI More articles by this author , Sameer SiddiquiSameer Siddiqui Detroit, MI More articles by this author , Jesse SammonJesse Sammon Detroit, MI More articles by this author , Shyam SukumarShyam Sukumar Detroit, MI More articles by this author , and Mani MenonMani Menon Detroit, MI More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.1011AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Long-term oncologic outcomes for patients undergoing robot-assisted radical prostatectomy (RARP) for prostate cancer (PCa) are limited. We evaluated oncologic outcomes in patients undergoing RARP at a high-volume tertiary center, with a focus on long-term biochemical recurrence free survival (BCRFS). METHODS A total of 4,062 consecutive patients underwent RARP from September 2001 to December 2008; 3,625 patients comprised the study cohort (excluding for: loss to follow-up, incomplete data, positive lymph nodes, neo-adjuvant and adjuvant treatment). Biochemical recurrence (BCR) was defined as a serum prostate-specific antigen ≥ 0.2 ng/ml with a confirmatory value. BCRFS, metastasis free survival (MFS) and cancer specific survival (CSS) were estimated using the Kaplan-Meier method. A Cox proportional hazards regression model was used to determine variables predictive of BCR. Event time distributions for the time to failure were compared using the log rank test. RESULTS Mean preoperative PSA was 6.1 ng/ml. Biopsy Gleason score was ≥ 7 in 44.4% of patients, pathologic Gleason grade was ≥ 7 in 64.5% of patients, and pathologic stage was ≥ pT3 in 30.3% of patients. BCR was noted in 305 (8.4%) patients; mean follow up was 32.9 months (median follow up - 25.7 months). Nine patients died of PCa (0.3%) and 16 patients developed metastatic disease (0.4%). Actuarial 3 and 5-year BCRFS was 91.6% and 87.7%. Actuarial 3 and 5-year CSS was 99.8% and 99.6%. CONCLUSIONS RARP appears to confer effective intermediate and long-term biochemical control. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e524-e525 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Craig Rogers Detroit, MI More articles by this author Mireya Diaz Detroit, MI More articles by this author Sameer Siddiqui Detroit, MI More articles by this author Jesse Sammon Detroit, MI More articles by this author Shyam Sukumar Detroit, MI More articles by this author Mani Menon Detroit, MI More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...